Abstract
The addition of a low dose of dopamine (DA) / serotonin1A (5-HT1A) partial agonists, including brexpiprazole (BREX), to selective 5-HT reuptake inhibitors (SSRI) or selective norepinephrine reuptake inhibitors (SNRI), like venlafaxine (VEN) is often used to successfully treat some treatment-resistant major depressive disorder (MDD) patients. Administration of these partial agonists could counterbalance the attenuating actions of SSRIs/SNRIs on firing activity of catecholamine neurons, resulting in reversal of deficient DA and NE tone that could be of crucial importance in the treatment of MDD. This study investigated whether BREX combined with VEN can induce a change in DA neurons activity that is initially not induced by VEN only.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
